Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma

WATERTOWN, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
March 08, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018

WATERTOWN, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
January 09, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-Rapamycin

Selecta’s Immune Tolerance SVP Platform Also Discussed in Scientific American’s January 2018 Issue WATERTOWN, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a...
January 02, 2018 08:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
January 02, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan

Dr. Werner Cautreels Plans Retirement at the End of 2018Dr. Omid Farokhzad Appointed Chairman of the Board WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc....
November 13, 2017 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Webcast Investor Conference Presentations This Week

WATERTOWN, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
November 07, 2017 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual MeetingPreparations for Phase 3 Program UnderwayReceived $7.5 Million From Spark...
October 31, 2017 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017

WATERTOWN, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
October 26, 2017 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Important Additions to Senior Leadership Team

Dr. John Leaman Named Chief Financial Officer and Head of Corporate StrategyStephen Smolinski Appointed Chief Commercial Officer WATERTOWN, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Selecta...
October 05, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations

WATERTOWN, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...